The use of cyclosporine in dermatology: Part I

被引：117
作者：
Amor, Karrie T. [1 ]
Ryan, Caitriona [2 ]
Menter, Alan [2 ]
机构：
[1] Univ Texas Houston, Dept Dermatol, Houston, TX USA
[2] Baylor Univ, Med Ctr, Dallas, TX USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2010年 / 63卷 / 06期
关键词：
atopic dermatitis; chronic urticaria; cyclosporine; psoriasis; pyoderma gangrenosum; LOW-DOSE CYCLOSPORINE; CHRONIC IDIOPATHIC URTICARIA; INTERMITTENT SHORT COURSES; PITYRIASIS-RUBRA-PILARIS; SEVERE ALOPECIA-AREATA; EROSIVE LICHEN-PLANUS; LONG-TERM TREATMENT; OF-THE-LITERATURE; ATOPIC-DERMATITIS; DOUBLE-BLIND;
D O I：
10.1016/j.jaad.2010.02.063
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
Cyclosporine is a calcineurin inhibitor that acts selectively on T cells. It has been used in dermatology since 1997 for its US Food and Drug Administration indication of psoriasis and off-label for various other inflammatory skin conditions, including atopic dermatitis, blistering disorders, and connective tissue diseases. In the last decade, many dermatologists have hesitated to use this important drug in their clinical practices because of its toxicity profile. The purpose of this article is to review the mechanism of action of cyclosporine and its current uses and dosing schedules. It is our goal to create a framework in which dermatologists feel comfortable and safe incorporating cyclosporine into their prescribing regimens.
引用
收藏
页码：925 / 946
页数：22
相关论文
共 160 条
[1]   Combined mycophenolate mofetil and cyclosporin therapy for severe recalcitrant psoriasis [J].
Ameen, M ;
Smith, HR ;
Barker, JNWN .
CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2001, 26 (06) :480-483
[2]  
Atakan N, 1998, J EUR ACAD DERMATOL, V11, P240, DOI 10.1016/S0926-9959(98)00085-3
[3]   Efficacy of cyclosporine on mucocutaneous manifestations of Behcet's disease [J].
Avci, O ;
Gurler, N ;
Gunes, AT .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1997, 36 (05) :796-797
[4]   Fumaric acid esters in severe psoriasis, including experience of use in combination with other systemic modalities [J].
Balasubramaniam, P ;
Stevenson, O ;
Berth-Jones, J .
BRITISH JOURNAL OF DERMATOLOGY, 2004, 150 (04) :741-746
[5]   TREATMENT OF 9 CASES OF PEMPHIGUS VULGARIS WITH CYCLOSPORINE [J].
BARTHELEMY, H ;
FRAPPAZ, A ;
CAMBAZARD, F ;
MAUDUIT, G ;
ROUCHOUSE, B ;
KANITAKIS, J ;
SOUTEYRAND, P ;
CLAUDY, AL ;
THIVOLET, J .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1988, 18 (06) :1262-1266
[6]  
Baskan E Bulbul, 2004, J Dermatolog Treat, V15, P164
[7]   Graham Little-Piccardi-Lassueur syndrome: effective treatment with cyclosporin A [J].
Bianchi, L ;
Vidolin, AP ;
Piemonte, R ;
Carboni, I ;
Chimenti, S .
CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2001, 26 (06) :518-520
[8]  
BIELECKA OK, 2009, ANN RHEUM DIS, V68, P620
[9]   Urticaria and cyclosporine [J].
Bonilla, PAG ;
Segade, JB ;
Torrijos, EG ;
Brito, FF .
ALLERGY, 2002, 57 (07) :650-651
[10]   BIOLOGICAL EFFECTS OF CYCLOSPORIN-A - NEW ANTILYMPHOCYTIC AGENT [J].
BOREL, JF ;
FEURER, C ;
GUBLER, HU ;
STAHELIN, H .
AGENTS AND ACTIONS, 1976, 6 (04) :468-475
12345678910